ONCT News and Press, Oncternal Therapeutics Inc. From 02/29/24

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S. finan...

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its dual...

2024-01-08 08:02:08 ET Oncternal Therapeutics Inc (ONCT) announced stock split at a ratio of 1-for-20 on 2024-01-08 ... Full story available on KlickAnalytics.com

2024-01-04 09:11:30 ET More on Oncternal Therapeutics Oncternal slips after early data for lymphoma therapy Oncternal stock jumps 9% on FDA fast track designation For further details see: Oncternal Therapeutics announces a reverse stock split

SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the compa...

2023-12-26 11:02:48 ET Oncternal Therapeutics ( NASDAQ: ONCT ) traded lower on Tuesday after announcing initial results from its Phase 1/2 study for autologous CAR T cell therapy, ONCT-808-101, in patients with B-cell lymphoma, a cancer affecting the immune system. Citing data f...

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the ...

2023-11-09 21:07:09 ET Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Conference Call November 09, 2023, 17:00 ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - Chief Medical Officer Conference Call Parti...

2023-11-09 16:16:15 ET More on Oncternal Therapeutics Oncternal stock jumps 9% on FDA fast track designation Seeking Alpha’s Quant Rating on Oncternal Therapeutics Historical earnings data for Oncternal Therapeutics Financial information for Oncternal ...